Forbes contributors publish independent expert analyses and insights. Kim Elsesser covers issues that impact women in the workplace. Organizations regularly use non-disclosure agreements (NDAs) to ...
NDA Preparation Strategy 2026: NDA 1 2026 exam is scheduled for April 12, 2026. With only a few months left, candidates should start preparing for the exam. Begin by reviewing the latest syllabus and ...
Singh maintained guidance that "we'll see top line results released before the end of this calendar quarter, so by the end of this calendar year" for PALISADE-3. Singh projected that top line results ...
Cytokinetics, Incorporated (CYTK) is gearing up to complete its rolling NDA submission of aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy [oHCM] in Q3 of 2024.
45% of workers surveyed said they'd been subject to a nondisclosure agreement. 39% of workers said they were bound by mandatory arbitration, according to a survey from Penn State. The agreements ...
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Eton Pharmaceuticals, Inc. announced positive results from its pivotal bioequivalence study of ET-600, a patented oral solution of desmopressin aimed at treating central diabetes insipidus. The study, ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results